Walgreens Boots Alliance Inc

Walgreens Boots Alliance — Q2 2020 Earnings Presentation

33 slides from Walgreens Boots Alliance's earnings presentation, Apr 2, 2020

  1. Slide 1: Fiscal 2020 Second Quarter Results

    Fiscal 2020 Second Quarter Results April 2, 2020

  2. Slide 2: Safe harbor and non-GAAP

    Safe harbor and non-GAAP Cautionary Note Regarding Forward-Looking Statements: Cautionary Note Regarding Forward-Looking Statements: All statements in these materials and the related presentation that are not historical including, without limitation, estimates of and goals for future tax, financial

  3. Slide 3: Overview

    Overview • Top priority of our team members is to serve our patients and customers, especially during this extraordinary time • Improved 2Q performance, especially RPU comparable sales • Continue to make progress against four strategic priorities − Accelerate digitalization of company − Transform an

  4. Slide 4: 2Q financial highlights

    2Q financial highlights • Adjusted EPS $1.52, -7.3% lower than prior year in constant currency • RPU improved pharmacy and retail comparable sales performance • Retail market remains challenging in the UK • Pharmaceutical Wholesale delivered continued sales & AOI growth • Transformational Cost Manag

  5. Slide 5: 2Q financial highlights

    2Q financial highlights Reported currency Constant currency 2Q20 Δ vs. 2Q19 Δ vs. 2Q19 $ in millions (except EPS and % change) Sales $35,820 + 3.7% + 4.1% Operating income: GAAP $1,233 - 18.7% Adjusted $1,703 - 12.0% - 12.0% Net earnings: GAAP $946 - 18.2% Adjusted $1,343 - 11.8% - 11.8% EPS: GAAP $

  6. Slide 6: First half FY20 financial highlights

    First half FY20 financial highlights Reported currency Constant currency 1H20 Δ vs. 1H19 Δ vs. 1H19 $ in millions (except EPS and % change) Sales $70,160 + 2.7% + 3.2% Operating income: GAAP $2,247 - 23.0% Adjusted $3,166 - 13.7% - 13.6% Net earnings: GAAP $1,791 - 21.4% Adjusted $2,565 - 11.8% - 11

  7. Slide 7: Retail Pharmacy USA – financials

    Retail Pharmacy USA – financials $ in millions (except %) 2Q20 Δ vs. 2Q19 1H20 Δ vs. 1H19 Sales $27,245 +3.8% $53,377 +2.7% Adj. gross profit $5,870 - 3.7% $11,622 - 4.3% Adj. SG&A % of sales 16.9% 0.8% 17.2% 0.7% Adj. operating margin 4.7% - 0.9%p 4.5% - 0.9%p Adj. operating income $1,267 - 12.9% $

  8. Slide 8: Retail Pharmacy USA – pharmacy

    Retail Pharmacy USA – pharmacy 2Q 2Q 1H 1H 2Q20 vs. 2Q19 Total Comparable Total Comparable Pharmacy sales + 5.3% + 3.7% + 4.1% + 3.1% Prescriptions + 3.7% + 4.9% + 2.6% + 3.8% • Improved comp prescription growth: 2Q +4.9% vs 1Q +2.8% • 2Q market share 21.0%; down 50 bps including impact from store o

  9. Slide 9: Retail Pharmacy USA – retail

    Retail Pharmacy USA – retail 2Q20 vs. 2Q19 2Q 1H Total retail sales - 0.3% - 1.2% Comp. retail sales + 0.6% + 0.1% • Sequential improvement in comparable sales growth − ex-tobacco and e-cigarettes up +1.9% − led by growth in Health & Wellness, aided by a favorable cold/cough flu season − slightly in

  10. Slide 10: Retail Pharmacy International – financials

    Retail Pharmacy International – financials Constant currency Constant currency $ in millions (except %) 2Q20 Δ vs. 2Q19 1H20 Δ vs. 1H19 Sales $3,056 - 1.7% $5,801 - 2.2% Adj. operating margin 6.5% - 1.9%p 4.8% - 1.8%p Adj. operating income $198 - 24.0% $276 - 29.1% Boots UK comp. pharmacy sales + 1.

  11. Slide 11: Pharmaceutical Wholesale – financials

    Pharmaceutical Wholesale – financials Constant currency Constant currency $ in millions (except %) 2Q20 Δ vs. 2Q19 1H20 Δ vs. 1H19 Sales $6,066 + 8.0% $12,072 + 8.1% Adj. operating margin 2.2% - 0.1%p 2.2% - 0.1%p Adj. operating income $235 + 5.2% $464 + 5.0% • Continued strong sales growth, led by

  12. Slide 12: Cash flow

    Cash flow $ in millions 1H20 Δ vs. 1H19 Operating cash flow $2,484 $1,289 Cash capital expenditure - $705 $89 Free cash flow $1,779 $1,378 • Free cash flow reflects strong working capital performance +$1.8bn and absence of prior year headwind relating to cash tax payment +$0.3bn • 2Q20 working capit

  13. Slide 13: Transformational Cost Management Program

    Transformational Cost Management Program On target to deliver in excess of $1.8 billion in annual cost savings by FY22 • Continue to focus on maximizing value of GNFR vendor contracts • Streamlined Boots UK field organization • Store closures: U.S. 116 closed of 200 planned, UK 40 closed of 200 plan

  14. Slide 14: Retail Pharmacy USA – initiatives

    Retail Pharmacy USA – initiatives • Kroger tiered grocery offering completed in 50 Walgreens stores and 17 Kroger Transform and stores with Walgreens health and beauty offering restructure retail • New personalized marketing approach, driving +1% lift to total retail sales in 2Q offering • Flagship

  15. Slide 15: Retail Pharmacy International – initiatives

    Retail Pharmacy International – initiatives Actions focused on premium beauty and digital acceleration Transform retail and • Strong share gains in premium beauty − Good performance in 26 Beauty reinvention stores develop new − Introduced 9 new beauty brands in 2Q, taking total to 48 healthcare serv

  16. Slide 16: COVID-19: Meeting customers and patients needs

    COVID-19: Meeting customers and patients needs • Ensuring locations remain open and safe − extra in-store cleaning and social distancing measures − dedicated U.S. store hours for seniors and care-givers • Working to ensure availability of critical products − fast-track products to stores and purchas

  17. Slide 17: COVID-19: Working with government and partners

    COVID-19: Working with government and partners • Partnering with U.S. government health officials to provide drive-thru testing • Partnering with NHS in the UK to provide testing for key workers • Donations to critical services • Providing health advice to customers on behalf of UK and U.S. governme

  18. Slide 18: COVID-19: Committed and focused moving forward

    COVID-19: Committed and focused moving forward • Leveraging our broad community footprint − more convenient access to key essential items − broad range of trusted over-the-counter health and wellness products − consistent supply of pharmaceuticals to provide customer availability • Supporting the he

  19. Slide 19: Business impacts are fluid & changing rapidly

    Business impacts are fluid & changing rapidly Walgreens − increased Rx demand, acceleration of scripts from future periods U.S. customer − strong initial March front of store sales buying behavior − initial gains concentrated in OTC, General Merchandising and Grocery; shifting Beauty, Photo and othe

  20. Slide 20: Business impacts are fluid & changing rapidly

    Business impacts are fluid & changing rapidly Higher expenses − increased store safety, cleaning & sanitation measures due to needed − enhanced temporary employee benefits operational − higher supply chain costs (DCs & stores; free on-line shipping) flexibility − deferring select programs & investme

  21. Slide 21: Refer to safe harbor and non-GAAP on page 2 and endnotes on page 22

    © 2020 Walgreens Boots Alliance, Inc. All rights reserved. Refer to safe harbor and non-GAAP on page 2 and endnotes on page 22 21

  22. Slide 22: Endnotes

    Endnotes • Please see appendix for reconciliations of non-GAAP financial measures and related disclosures ◦ The company presents certain information related to current period operating results in “constant currency,” which is a non-GAAP financial measure. These amounts are calculated by translating

  23. Slide 23: Appendix

    Appendix The information on the following pages provides reconciliations of the supplemental non-GAAP financial measures, as defined under SEC rules, presented in this presentation to the most directly comparable financial measures calculated and presented in accordance with generally accepted accou

  24. Slide 24: Reconciliation of Non-GAAP financial measures

    Reconciliation of Non-GAAP financial measures Walgreens Boots Alliance, Inc. and Subsidiaries Supplemental Information (unaudited) (in millions) NET EARNINGS Three months ended Change vs. 2Q19 Six months ended Change vs. FY19 February 29, 2020 February 28, 2019 Amount Percent February 29, 2020 Febru

  25. Slide 25: Reconciliation of Non-GAAP financial measures

    Reconciliation of Non-GAAP financial measures Walgreens Boots Alliance, Inc. and Subsidiaries Supplemental Information (unaudited) DILUTED NET EARNINGS PER SHARE Three months ended Change vs. 2Q19 Six months ended Change vs. FY19 February 29, 2020 February 28, 2019 Amount Percent February 29, 2020 F

  26. Slide 26: Reconciliation of Non-GAAP financial measures

    Reconciliation of Non-GAAP financial measures Walgreens Boots Alliance, Inc. and Subsidiaries Supplemental Information (unaudited) (in millions) Three months ended February 29, 2020 Retail Pharmacy Retail Pharmacy Pharmaceutical Walgreens Boots USA International Wholesale1 Eliminations Alliance, Inc

  27. Slide 27: Reconciliation of Non-GAAP financial measures

    Reconciliation of Non-GAAP financial measures Walgreens Boots Alliance, Inc. and Subsidiaries Supplemental Information (unaudited) (in millions) Three months ended February 28, 2019 Retail Pharmacy Retail Pharmacy Pharmaceutical Walgreens Boots USA International Wholesale1 Eliminations Alliance, Inc

  28. Slide 28: Reconciliation of Non-GAAP financial measures

    Reconciliation of Non-GAAP financial measures Walgreens Boots Alliance, Inc. and Subsidiaries Supplemental Information (unaudited) (in millions) Six months ended February 29, 2020 Retail Pharmacy Retail Pharmacy Pharmaceutical Walgreens Boots USA International Wholesale1 Eliminations Alliance, Inc.

  29. Slide 29: Reconciliation of Non-GAAP financial measures

    Reconciliation of Non-GAAP financial measures Walgreens Boots Alliance, Inc. and Subsidiaries Supplemental Information (unaudited) (in millions) Six months ended February 28, 2019 Retail Pharmacy Retail Pharmacy Pharmaceutical Walgreens Boots USA International Wholesale1 Eliminations Alliance, Inc.

  30. Slide 30: Reconciliation of Non-GAAP financial measures

    Reconciliation of Non-GAAP financial measures Walgreens Boots Alliance, Inc. and Subsidiaries Supplemental Information (unaudited) (in millions) EQUITY EARNINGS IN AMERISOURCEBERGEN Three months ended Six months ended February 29, 2020 February 28, 2019 February 29, 2020 February 28, 2019 Equity ear

  31. Slide 31: Reconciliation of Non-GAAP financial measures

    Reconciliation of Non-GAAP financial measures Walgreens Boots Alliance, Inc. and Subsidiaries Supplemental Information (unaudited) (in millions) ADJUSTED EFFECTIVE TAX RATE Three months ended February 29, 2020 Three months ended February 28, 2019 Earnings before Earnings before income tax Income tax

  32. Slide 32: Reconciliation of Non-GAAP financial measures

    Reconciliation of Non-GAAP financial measures Walgreens Boots Alliance, Inc. and Subsidiaries Supplemental Information (unaudited) (in millions) FREE CASH FLOW Three months ended Six months ended February 29, 2020 February 28, 2019 February 29, 2020 February 28, 2019 Net cash provided by operating a

  33. Slide 33: Currency sensitivity

    Currency sensitivity Exchange Rates/Impact FY19 Dec '19 Sensitivity Mar '20 Sensitivity GBP/USD 1.28 1.32 1.26 EUR/USD 1.13 1.11 1.10 TRY/USD 0.18 0.17 0.16 Fx Sales Impact vs. FY19 ~$50m/~0.0% ~($925m)/~(0.7%) Fx Adj. Operating Income Impact vs. FY19 ~$20m/~0.3% ~($15m)/~(0.2%) Fx Adj. EPS Impact v

Walgreens Boots Alliance — Q2 2020 Earnings Presentation on 6ix